TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05613686

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: repetitive transcranial magnetic stimulation
Description: Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technology. High and low frequencies of rTMS could modulate the excitability of the cerebral cortex. Theta burst stimulation (TBS) has achieved a similar effect to traditional rTMS mode. Intermittent TBS (iTBS) could upregulate cortical excitability of the primary motor cortex (M1) and continuous TBS (cTBS) with inhibitory effect.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation
Description: Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technology. High and low frequencies of rTMS could modulate the excitability of the cerebral cortex. Theta burst stimulation (TBS) has achieved a similar effect to traditional rTMS mode. Intermittent TBS (iTBS) could upregulate cortical excitability of the primary motor cortex (M1) and continuous TBS (cTBS) with inhibitory effect.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transcranial magnetic stimulation
Description: Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technology. High and low frequencies of rTMS could modulate the excitability of the cerebral cortex. Theta burst stimulation (TBS) has achieved a similar effect to traditional rTMS mode. Intermittent TBS (iTBS) could upregulate cortical excitability of the primary motor cortex (M1) and continuous TBS (cTBS) with inhibitory effect.
Study: NCT06244043

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Initial Coaching Call
Description: Participant will receive initial coaching call with a team member. This coaching call will either be interventional (i.e., include content intended to prompt their adherence and benefit from the HMP app) or informational (i.e., include content intended to control for the time and attention of attending a coaching session, but not intended to provide specific benefits).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Initial Coaching Call
Description: Participant will receive initial coaching call with a team member. This coaching call will either be interventional (i.e., include content intended to prompt their adherence and benefit from the HMP app) or informational (i.e., include content intended to control for the time and attention of attending a coaching session, but not intended to provide specific benefits).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Email Support
Description: Email-based support throughout study period

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Email Support
Description: Email-based support throughout study period

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Text Messages
Description: All participants with receive text messages encouraging them to engage in the practices taught in the app.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Text Messages
Description: All participants with receive text messages encouraging them to engage in the practices taught in the app.
Study: NCT05520567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Oral
Study: NCT06244043

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Text Messages
Description: All participants with receive text messages encouraging them to engage in the practices taught in the app.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Text Messages
Description: All participants with receive text messages encouraging them to engage in the practices taught in the app.
Study: NCT06449066

Intervention type: OTHER
Intervention: Non applicable
Description: Non applicable (data collection)
Study: NCT06560528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: combination with Disitamab Vedotin and with Tislelizumab and Capecitabine
Description: Subjects will receive Disitamab Vedotin combined with Tislelizumab and Capecitabine for 3 cycles (Q3W) in the neoadjuvant phase and 5 cycles (Q3W) of treatment in the adjuvant phase.~1. Disitamab Vedotin：2.5 mg/kg，Q3W；~2. Tislelizumab：200 mg，Q3W；~3. Capecitabine：1000 mg /m2, PO, bid d1-14, Q3W.
Study: NCT06476977

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dorsal webspace combined corticosteroid and anesthetic injection
Description: The dorsal webspace injection consists of a 1cc mixture of 0.5cc triamcinolone (Kenalog) 10mg/mL and 0.5cc 1% lidocaine for analgesic purposes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Palmar combined corticosteroid and anesthetic injection
Description: The palmar injection consists of a 1cc mixture of 0.5cc triamcinolone (Kenalog) 10mg/mL and 0.5cc 1% lidocaine for analgesic purposes.
Study: NCT05520567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gilteritinib
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Oral
Study: NCT06133920

Intervention type: OTHER
Intervention: Early Range of Motion
Description: The early range of motion group will be given a sling for comfort after their surgery. They will be told they can use their arm as tolerated and can remove the sling when comfortable immediately after surgery. They will be allowed to start passive range of motion, active assisted range of motion, and gentle active range of motion with therapy as tolerated with the exception of no internal rotation. They will also not be allowed to strengthen until 12 weeks after surgery. They will get formal physical therapy and be given a home exercise program as well that will be directed by their physical therapist

Intervention type: OTHER
Intervention: Immobilization
Description: The immobilization group will be placed in a shoulder abduction sling immediately after surgery for four weeks. They will be allowed to start gentle passive range of motion with forward flexion to 120 degrees, abduction to 90 degrees, and external rotation to 30 degrees. They will receive a home exercise program and formal physical therapy with these limits.~When they come out of the sling at four weeks they will start active range of motion and active assisted range of motion. They cannot internally rotate until 10 weeks after surgery. No formal strengthening until 3 months after surgery.
Study: NCT06429540

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Partially Demineralized Dentin Block
Description: The extracted tooth will be dried using air, then ground and partially demineralized with the Tooth Transformer device following the manufacturer's protocol. Dentin particles will be obtained with dimensions of 400-800 μm. The partially demineralized dentin will then be prepared by cutting the Leukocyte-Platelet Rich Fibrin (L-PRF) membranes into small pieces and mixing them with the dentin particles. Liquid fibrinogen will be added to the homogeneous mixture. Within a few minutes, the fibrinogen will convert into fibrin primarily from the activated blood platelets in the chopped L-PRF membranes. This process will effectively trap the biomaterial and the L-PRF pieces, forming the dentin block. After that, the sockets will be carefully packed with the dentin block and it will be covered with L-PRF membrane. To ensure stability and prevent displacement, the wounds will be secured using non-resorbable sutures.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Xenograft
Description: In the control group using the Xenograft, the same extraction and socket debridement procedure will be performed. Following that, the extraction socket will be thoroughly filled with deproteinized bovine bone mineral, and a collagen membrane will be employed to cover the socket. The membrane will be shaped to extend 2-3 mm beyond the margins of the extraction socket and positioned just beneath the marginal mucosa. To ensure its stability, a cross-suture will be performed, securing the membrane in place.
Study: NCT06562933

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham vacuum
Description: Participants will undergo a total of 10 treatment sessions over two weeks, with one session per day, five days a week. Two-channel four vacuum electrodes will be placed on the neck so that the painful area remains in the middle. The vacuum electrodes will apply continuous vacuum mode for only 10 minutes without delivering interferential current. Following the sham vacuum therapy, a hot pack will be applied to the painful neck area for 20 minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Interferential Current Therapy Vacuum Electrodes
Description: Participants will undergo a total of 10 treatment sessions over two weeks, with one session per day, five days a week. Two-channel four vacuum electrodes will be placed on the neck so that the painful area remains in the middle. Interferential current therapy with a 4000 Hz carrier frequency and 50 Hz amplitude-modulated frequency will be applied for 10 minutes using the vacuum electrodes. After the interferential current therapy, a hot pack will be applied to the painful neck area for 20 minutes.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Interferential Current Therapy Carbon-silicon Pad Electrodes
Description: Participants will undergo a total of 10 treatment sessions over two weeks, with one session per day, five days a week. Two-channel four carbon-silicon pad electrodes will be placed on the neck so that the painful area remains in the middle. Interferential current therapy with a 4000 Hz carrier frequency and 50 Hz amplitude-modulated frequency will be applied for 10 minutes using the carbon-silicon pad electrodes. Following the interferential current therapy, a hot pack will be applied to the painful neck area for 20 minutes.
Study: NCT06536257

Intervention type: OTHER
Intervention: Predictive model
Description: Patient who have not had immunotherapy will have tumour tested using the predictive model. This determines whether patients are likely to respond, or not to respond to immunotherapy. Results of the predictive model will be compared with the actual response to immunotherapy when this has been completed.

Intervention type: OTHER
Intervention: Predictive model
Description: Patient who have not had immunotherapy will have tumour tested using the predictive model. This determines whether patients are likely to respond, or not to respond to immunotherapy. Results of the predictive model will be compared with the actual response to immunotherapy when this has been completed.
Study: NCT05749588

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G1: SHR-A1811
Description: G1: an anti-HER2 antibody-drug conjugate (ADC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H1: TROP2 ADC
Description: H1: an Trophoblast cell-surface antigen 2 (TROP2) ADC
Study: NCT05510986

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl group
Description: Dilute fentanyl hydrochloride injection (1ml:0.1mg) with 0.9% normal saline to 10μg/ml, 1μg/kg fentanyl is slowly injected intravenously 10 minutes before the end of the operation, and the administration speed is not less than 5 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone Hydrochloride group
Description: Dilute Oxycodone Hydrochloride injection (1ml:10mg) with 0.9% normal saline to~1mg/ml, 0.1mg/kg Oxycodone Hydrochloride is slowly injected intravenously 10 minutes before the end of the operation, and the administration speed is not less than 5 minutes.
Study: NCT06536257

Intervention type: OTHER
Intervention: Predictive model
Description: Patient who have not had immunotherapy will have tumour tested using the predictive model. This determines whether patients are likely to respond, or not to respond to immunotherapy. Results of the predictive model will be compared with the actual response to immunotherapy when this has been completed.
Study: NCT05053854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: During dose escalation, doses of talazoparib that can be administered are 0.1mg, 0.25mg, 0.5mg or 1mg oral daily. Talazoparib will be given on days 2-6 of each cycle of 177Lu-DOTA-Octreotate for cycles 2-4, every 8 weeks
Study: NCT05790824

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spa therapy
Description: The RH2 rheumatology treatment protocol will propose treatments that can be carried out with water from the SL5 borehole and will be composed of:~* 54 treatments among the following treatments:~  * Swimming pool, 15 minutes (code 201)~ * Bath with aerobath, 10 minutes (code 205)~ * Bath with immersion shower, 10 minutes (code 206)~ * Cataplasm in multiple local application, 10 minutes (code 408)~* 18 sessions of mobilization pool, 15 minutes (code 601)
Study: NCT05674734

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 4FM Acceptance Training
Description: 4FM Acceptance Training, therapeutic intervention in the form of an additional to TAU module - 12 (1,5 hour) group meetings in the form of 4FM Acceptance Training at Day Care Units at IPIN Mental Health Centre for Mokotów and IPiN (1 meeting weekly).
Study: NCT06225921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Adebrelimab will be given at a dose of 20 mg per kilogram of body weight every three weeks on day 23 of a planned 28-day cycle, and two doses before surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebrelimab
Description: Adebrelimab will be given at a dose of 20 mg per kilogram of body weight every three weeks on day 23 of a planned 28-day cycle, and two doses before surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalpiciclib 100mg
Description: Dalpiciclib will be given at a dose of 100 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for two cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalpiciclib 150mg
Description: Dalpiciclib will be given at a dose of 150 mg every day orally with three weeks on and one week off. Four weeks is a cycle and it will be given for two cycles.
Study: NCT05520567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Subcutaneous injection or intravenous infusion
Study: NCT06302114

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Assessment of overhead athletes
Description: Assessment of medicine ball forward throw, Y balance test, Range of motion of the shoulder (internal and external rotation), strength of internal and external rotator muscles.
Study: NCT05520567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Subcutaneous injection or intravenous infusion
Study: NCT04454229

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Direct oral penicillin challenge
Description: The patient will receive a single dose of oral penicillin, following baseline vital signs.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Routine management as per the treating clinicians that include skin prick and intradermal beta-lactam testing, followed by oral penicillin challenge in the setting of negative skin testing.
Study: NCT04652856

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Brain Stimulation
Description: Electrical Brain Stimulation (EBS) will be used to disrupt local neural activity in inferior temporal regions (ITC), parahippocampal cortex (PHC), the hippocampus, and control regions. The effects of EBS will be examined on attention and eye movement behavior, and all participants will receive both EBS and sham electrical brain stimulation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham Electrical Brain Stimulation
Description: Sham electrical brain stimulation (SEBS) will be applied to inferior temporal regions (ITC), parahippocampal cortex (PHC), the hippocampus, and control regions. The effects of SEBS will be examined on attention and eye movement behavior, and all participants will receive both SEBS and EBS.
Study: NCT06155721

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality Cognitive Stimulation Program
Description: Intervention Type: Device Intervention Name: Virtual Reality Cognitive Stimulation Program Description: This program utilizes virtual reality to conduct cognitive stimulation exercises aimed at improving memory, executive functions, and attention in individuals with Mild Cognitive Impairment (MCI). It includes interactive tasks such as virtual shopping, payment simulations, and recipe sequencing, along with 360-degree video sessions for attention and episodic memory training.
Study: NCT06558942

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: incisional negative pressure wound technology
Description: Negative pressure device used directly on closed or sutured incisions
Study: NCT06358950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 2680
Description: Oral tablet of ALKS 2680 for once daily administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 2680
Description: Oral tablet of ALKS 2680 for once daily administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALKS 2680
Description: Oral tablet of ALKS 2680 for once daily administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet containing matching placebo for once daily administration
Study: NCT04603482

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resourcefulness Training
Description: A cognitive-behavioral intervention presented within an audiovisual format that consists of teaching and reinforcing personal (self-help) and social (help-seeking) resourcefulness skills.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback Training
Description: Use of a heart-rate variability (HRV) tracking device to enable one to learn to alter physiology to improve health. Devices are used to measure physiological activity, e.g., breathing and heart function, and provide rapid, accurate feedback to the user, thereby enabling desired physiological changes that can endure over time without continued use of the device and to continue to influence behavior.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diversional Activites
Description: An audiovisual format presenting 12 activities for adults including but not limited; crossword puzzles, reading, gardening, exercise, cooking/baking, board games, learning a new language, social activities, online games, etc.
Study: NCT06561724

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Biscuits maltodextrin
Description: Biscuits includes maltodextrin

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Biscuits includes prebiotics tartoufa inulin
Description: Biscuits prebiotics

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Biscuits includes prebiotics chicory inulin
Description: Biscuits prebiotics
Study: NCT06081062

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fabagal® (Agalsidase beta)
Description: 1 mg/kg every 2 weeks for 12 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator (Agalsidase beta)
Description: 1 mg/kg every 2 weeks for 12 months
Study: NCT06072313

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Monopolar electrical diathermy plus therapeutic exercise
Description: The Experimental Group will undergo two sessions per week of monopolar electrical diathermy by radiofrequency emission (MDR) using the Physicalm® device and one session of therapeutic neck exercise per week.
Study: NCT05600907

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JSP191
Description: A monoclonal antibody that targets human CD117
Study: NCT05925491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab administration in combination with chemotherapy for 3 cycles, followed by standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 75mg/mq in combination with pembrolizumab 200 mg and docetaxel 75 mg/mq every three weeks (Q3W) for 3 courses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/mq in combination with pembrolizumab 200 mg and cisplatin 75 mg/mq every three weeks (Q3W) for 3 courses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 5 alternative to Cisplatin if toxicities occur.
Study: NCT06459258

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motion-triggered NMES training protocol
Description: Experimental group subjects undergo a motion-triggered NMES shoulder strengthening training program (3x/week, 30 minutes for 6 weeks) using the Shoulder Pacemaker (NCS Lab Srl, Modena, Italy), a motion activated stimulation device to strengthen muscular disbalances. This is accomplished through varying neuromuscular electrical stimulation intensity based on the angle of motion of the arm producing subtetanic contraction and provoking supraspinal neural adaptations. Electrode placement: electrode 1, inferior to the scapular spine (infraspinatus, teres minor, + posterior deltoid); electrode 2, medial to the medial scapula border (lower trapezius + rhomboids) . Sets x repetitions: 3x20 Levels: Level 1-3; Exercise 1: L1: Supported row, L2: Front raises in 45°, L3 Front raises (thumbs up) Exercise 2: L1: Resisted front raises, L2: Crossbody resisted raises, L3: Crossbody; forehand swing; Exercise 3: L1: Rear dealt fly, L2: Single arm resisted row, L3: Underhand volleyball

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-Motion-triggered NMES training protocol
Description: Arm Description: Subjects of the control group undergo a conventional standardized strength training program (3x/week, 30 minutes for 6 weeks) with concentric, eccentric, and functional training exercises.
Study: NCT06318117

Intervention type: OTHER
Intervention: Rice infant formula
Description: Any commercially available rice infant formula whom the pediatrician has previously deemed, or is deeming it useful to consume.

Intervention type: OTHER
Intervention: Rice infant formula
Description: Any commercially available rice infant formula whom the pediatrician has previously deemed, or is deeming it useful to consume.
Study: NCT04874454

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: evaluate the vocal cord movement among the stroke patients
Study: NCT06072313

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Exercise
Description: The exercise program will consist of standing, seated and supine postures, starting with simple postures and moving on to more complex ones. Participants will be asked to focus on their posture, joint positions and muscle tension in each exercise posture.
Study: NCT06166823

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMR alert
Description: EMR alert for medication optimization
Study: NCT05990530

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: YD02-2022
Description: Human islet cells were isolated and expanded in vitro to generate islets containing all types of pancreatic endocrine cells and possessing comparable function of human islets. These islet cells will be infused into the hepatic portal vein.